Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients.
about
Glucarpidase to combat toxic levels of methotrexate in patientsRecent new drug approvals. Part 1: drugs with pediatric indicationsWhat can clinicians learn from therapeutic studies about the treatment of acute oral methotrexate poisoning?Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy.Hypersensitivity reaction to high-dose methotrexate and successful rechallenge in a pediatric patient with osteosarcoma.Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients.Glucarpidase (voraxaze), a carboxypeptidase enzyme for methotrexate toxicity.Preventing and Managing Toxicities of High-Dose MethotrexateEfficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy.Methotrexate nephrotoxicity: Novel treatment, new approach.MDR1 and OAT1/OAT3 mediate the drug-drug interaction between puerarin and methotrexate.Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance.Hispanic ethnicity as a risk factor for requiring glucarpidase rescue in pediatric patients receiving high-dose methotrexate.Engineering carboxypeptidase G2 circular permutations for the design of an autoinhibited enzyme.Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.Evaluation of a Methotrexate Chemiluminescent Microparticle Immunoassay: Comparison to Fluorescence Polarization Immunoassay and Liquid Chromatography-Tandem Mass Spectrometry.
P2860
Q24605014-EBDFE3A4-A4E0-49D4-B3E9-3A239D7CD772Q28709081-46493D30-154E-46B8-9E89-784801D9ACB3Q30397448-60F9472F-BB7E-4F5D-945C-69BAFCE584A4Q33557148-B070CDEA-B70F-49F9-AE1E-1E90DA2BAEC2Q34712463-67051E1A-C0C3-459D-97FF-9DC57C97BDA1Q36630079-3C9B3A66-0723-45C4-973E-8AA604A5DF26Q37419418-AB732A80-E057-4080-A7D6-6B070A089684Q37496637-4F6F336D-8C20-4DDC-8C30-6902D07FA165Q37708963-8B7AFB16-98A8-4C1D-9877-B95699AFEA99Q38164321-D7857EFD-55EB-44C5-8ED4-53A49D76F804Q39062211-4824E11C-1DC1-4927-9B20-944E8BE6253CQ46446111-0CC32C67-982C-469D-AADA-09DD604FE1FFQ48336764-275E7D7B-CF08-4115-9E54-E651FB1B4304Q48845824-76800EBD-E95D-4654-B07A-FB486C7DB17BQ51012681-E588D4B0-8E07-4C1D-ADB8-FB9E289689B7Q51274763-C4904356-338A-473B-986A-47750D13B22B
P2860
Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Resumption of high-dose methot ...... n pediatric oncology patients.
@ast
Resumption of high-dose methot ...... n pediatric oncology patients.
@en
Resumption of high-dose methot ...... n pediatric oncology patients.
@nl
type
label
Resumption of high-dose methot ...... n pediatric oncology patients.
@ast
Resumption of high-dose methot ...... n pediatric oncology patients.
@en
Resumption of high-dose methot ...... n pediatric oncology patients.
@nl
prefLabel
Resumption of high-dose methot ...... n pediatric oncology patients.
@ast
Resumption of high-dose methot ...... n pediatric oncology patients.
@en
Resumption of high-dose methot ...... n pediatric oncology patients.
@nl
P2093
P2860
P356
P1433
P1476
Resumption of high-dose methot ...... n pediatric oncology patients.
@en
P2093
Alberto S Pappo
Alejandro R Molinelli
Anthony M Christensen
Clinton F Stewart
Deborah A Ward
James M Hoffman
Jennifer L Pauley
John C Panetta
Kristine R Crews
Mary V Relling
P2860
P304
P356
10.1002/CNCR.27378
P407
P577
2012-01-17T00:00:00Z